Oculis Holding AG (OCS) EBT Growth (1y) (2023 - 2026)

Oculis Holding AG (OCS) EBT Growth (1y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Growth (1y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -0.10%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 1,140.26%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 71.54%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -8.15%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 88.57%
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Alnylam Pharmaceuticals 35.71 Bn 32.70 Bn 959.66 Mn 9,460.35%

Historic Data

Download Data
DateValue
Mar 31, 2026 -0.10%
Dec 31, 2025 10.11%
Sep 30, 2025 9.57%
Jun 30, 2025 -33.33%
Mar 31, 2025 -100.69%
Dec 31, 2024 -133.82%
Sep 30, 2024 -117,219.62%
Jun 30, 2024 -62.11%
Mar 31, 2024 62.91%
Dec 31, 2023 -47.75%
Sep 30, 2023 -92.66%
Jun 30, 2023 -11.13%